fragment (1.8 kb) containing acyA was subcloned with pIJ350. A high-level tylosin producer, Streptomycesfradiae MBBF, transformed with the plasmid could produce a hybrid macrolide, 3-0-acetyltylosin, most efliciently.
Several reports have demonstrated production of specific components or new types of antibiotics by disruption of targeted genes or introduction of genes encoding antibiotic modification enzymes, respectively, in actinomycetes (2, [10] [11] [12] . The use of such a genetically engineered strain would be more beneficial than the indirect and conventional bioconversion method for production of a hybrid macrolide antibiotic.
3-O-Acetyl 4"-O-isovaleryltylosin (AIV) (Fig. 1B) is an industrially important 16-membered macrolide antibiotic that is widely used by veterinarians and is known to be effective for preventing the growth of tylosin-resistant bacteria (9) . The current process for producing AIV consists of two steps of fermentation: first, tylosin fermentation by Streptomycesfradiae and second, acyl conversion by a mutant strain of Streptomyces thermotolerans that does not produce carbomycin (Fig. 1A) (8) . Two distinct acyltransferases (3-O-acyltransferase and 4-0-acyltransferase) of macrolide antibiotics have key roles in this acyl conversion. We have studied the possibility of innovating direct fermentation in place of the indirect method by use of a genetically engineered strain. During this study, we cloned from S. thermotolerans the 4"-O-acyltransferase gene (acyBl) together with its regulatory gene (acyB2) (1) . acyBI was found to be identical to carE, whose sequence has been published elsewhere by other workers (2) . A macrolide biosynthesis gene, mdmC, encoding 3-O-acetyltransferase, was recently cloned from midecamycin-producing Streptomyces mycarofaciens by Hara and Hutchinson (3) , but it has not yet been cloned from carbomycin-producing S. thermotolerans.
In this communication, we report the production of 3-0-acetyltylosin (3-AT) by a transformant of S. fradiae, into which the macrolide antibiotic biosynthesis gene acyA, which encodes 3-O-acyltransferase, cloned from S. thermotolerans was introduced. This is the preliminary step for the direct production of AIV.
Chromosome walking and cloning of acyA. For preparation of the cosmid library, chromosomal DNA was isolated from S. thermotolerans TH475, a mutant of carbomycin-producing strain ATCC 11416 in which carbomycin-lactone formation is blocked but acyltransferase activities are intact. Escherichia coli cosmid pHC79 (4) (Boehringer Mannheim, Penzberg, Germany) and E. coli HB101 were used as a vector and a host strain, respectively. Packaging to X phage was done by using the Giga Pack Gold in vitro packaging kit (Stratagene, La Jolla, Calif.). Transduction to E. coli, labeling of DNA, colony hybridization, and other basic methods for genetic manipulation were done by following the procedures of Maniatis et al. (7) and Hopwood et al. (5) . On primary screening of the cosmid library, with a 1.0-kb SacI-EcoRI fragment (3' region of acyBl) of pAOY-17 (1) as a probe, some positive clones were isolated. One of the clones, carrying pSE26, was selected for an additional walking step. Secondary screening of the library was done to extend the cloned region. A probe for the cloned region was prepared from a terminal region (1.0-kb BamHI fragment) of the insert of pSE26. One of the positive secondary clones, carrying pBM73, which shared only a small region with pSE26 (<0.5 kb), was selected. The total length covered by the two cosmids (pSE26 and pBM73) was estimated to be about 80 kb. They were partially digested with Sall, ligated into the XhoI site of pIJ922 (5), and then transformed into Streptomyces lividans TK24 (5) . The transformants were grown on GYM plates (1.0% glucose, 0.5% yeast extract, 1.0% malt extract, 1.5% agar; pH 7.2) supplemented with thiopeptin to 50 ,ug/ml. Next, leucomycin A1 was overlaid on the plates together with soft nutrient agar (5) (Fig. 2) . A plasmid harboring a 3.2-kb Sall insert was isolated from the clone and designated p53A (Fig. 3) . S. lividans transformed with p53A converted leucomycin A1 or tylosin added exogenously to the growth medium into leucomycin A3 or 3-AT, respectively. The insert of p53A was hybridized with pBM73 but not hybridized with pSE26 on Southern blot analysis (data not shown).
Expression of acyA in S. fradiae and production of hybrid macrolide antibiotic. A 1.8-kb BamHI-SalI fragment from the 3.2-kb region containing acyA was isolated from a 0.8% agarose gel and purified with GENE CLEAN II (Bio 101, Inc., La Jolla, Calif.). The DNA fragment was subcloned into a modified pUC18, the SmaI site of which was replaced by a PstI site with a PstI linker. Next, a 1.8-kb PstI fragment was recloned from the resulting plasmid into the single PstI site of pIJ350 (6) to construct pMAA25 (Fig. 3) . S. lividans transformed with pMAA25 expressed the macrolide 3-O-acyltransferase without any loss of activity compared with that of S. lividans transformed with p53A (Fig. 2) . To acquire a strain that produces 3-AT directly, the tylosin producer S. fradiae MBBF, a high-level tylosin producer derived from ATCC 19609 by N-methyl N'-nitro N-nitrosoguanidine (NTG) mutagenesis, was transformed with pMAA25. One of the stable pMAA25 transformants was cultivated in seed medium (2% potato starch, 2% soybean meal, 0.1% yeast extract, 0.05% K2HPO4, 0.05% MgSO4, 0.3% CaCO3) at 28°C for 3 days and then in oil medium (6% rape oil, 2.5% dry yeast, 0.1% CaCO3, 0.1% choline chloride) at 28°C for 10 days. The culture broth was diluted 20-fold with 0.1 M phosphate buffer (pH 9.0), and 2 ml of the solution was extracted with an equal volume of ethylacetate. After evaporation of the extract, the dry pellet was dissolved with 1 ml of 80% acetonitrile. Next, 10 ,ul of the solution was injected for high-performance liquid chromatography (HPLC). The column (YMC-Pack ODS-A; inner diameter, 6 mm; length, 150 mm; YMC Co., Ltd., Kyoto, Japan) was developed with 0.85 M NaClO4 (pH 2.5)-acetonitrile (17:15), and the flow rate was 1.5 ml/min. Tylosin and its derivatives were detected by UV absorbance at 280 nm. The analysis of the culture broth showed a successful production of the hybrid macrolides, while control strains (the host strain with no plasmid and the transformant with pIJ350) produced no acyl macrolides (Fig. 4) . The strain into which acyA was introduced produced 3-AT principally and 3-O-acetylrelomycin (3-0-acetyl 20-dihydrotylosin) as a minor product. Production of macrolides in batch culture (10th day) of transformants is summarized in Table 1 . Epp et al. succeeded in producing 4"-O-isovalerylspiramycin directly from spiramycin-producing Streptomyces ambofaciens, into which the carE gene from S. thermotolerans was introduced (2) . Their data showed that the unconverted spiramycin was also observed in the total products. No description of how much of the hybrid macrolide the recombinant strain could produce was found. We speculate that a lower level of endogenous isovaleryl coenzyme A (CoA) than acetyl-CoA might have been responsible for the imperfect 4"-O-isovalerylation of spiramycin. Our strain satisfied both qualitative and quantitative demands: no unacylated antibiotic was produced, and the efficiency with which the hybrid antibiotic was produced was noticeable (Table 1) .
Our final aim is to generate an AIV-producing strain by expression of both acyA and acyBl-acyB2 genes simultaneously We thank H. Asou-Takahashi for excellent technical assistance.
